We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The expanded recall of Boston Scientific’s drug-eluting Taxus stent will result in a nearly $100 million hit on the firm’s second-quarter earnings, company officials confirmed.
Boston Scientific on July 2 recalled 200 units of its drug-eluting Taxus Express2 stent due to a catheter balloon deflation problem that caused one patient death and serious injuries to 16 others.